A Phase 1, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants With Solid Tumors
Mersana Therapeutics
Summary
A Study of XMT-1660 in Solid Tumors
Description
This first-in-human (FIH) study will test the safety and side effects of a drug called XMT-1660. A side effect is anything a drug does to the body besides treating the disease. Participants in the study will have cancer that has come back after a period of time during which the cancer could not be detected (recurrent), spread in the body near where it started (advanced) or spread through the body (metastatic). The study will have two parts. The first part called Dose Escalation will find out how much XMT-1660 should be given to participants. The second part called Dose Expansion will use the…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Recurrent or advanced solid tumor and has disease * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Participants in DES must have at least one non-target lesion as defined by RECIST version 1.1. Participants in Backfill Cohorts and EXP must have at least one measurable disease (target) lesion as defined by RECIST version 1.1. * Tumor tissue, either archival or from a fresh tumor biopsy, available for testing or be willing to undergo a minimally invasive tumor biopsy to obtain tumor tissue for local testing, if not medically contraindicated, prior to…
Interventions
- DrugXMT-1660
XMT-1660 will be administered through a vein in your arm or port catheter (intravenously)
Locations (26)
- Mayo Clinic Comprehensive Cancer CenterPhoenix, Arizona
- UC Irvine Health-Chao Family Comprehensive Cancer CenterOrange, California
- UCSF Helen Diller Family Comprehensive Cancer CenterSan Francisco, California
- UCLA David Geffen School of Medicine, Division of Hematology/OncologySanta Monica, California
- Mayo Clinic - JacksonvilleJacksonville, Florida
- Florida Cancer SpecialistsSarasota, Florida